Tuesday - July 07, 2026

Category Archives: Science

Human Papillomavirus-positive Oropharyngeal Cancer Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s, “Human Papillomavirus-positive Oropharyngeal Cancer Pipeline Insight 2026” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Human Papillomavirus-positive Oropharyngeal Cancer pipeline landscape. It covers the Human Papillomavirus-positive Oropharyngeal Cancer pipeline drug profiles, including clinical and nonclinical … Continue reading →

Perennial Allergic Rhinitis Market is Projected to Boom by 2036 Owing to the Launch of Novel Therapies | DelveInsight

The market dynamics for Perennial Allergic Rhinitis is witnessing steady growth driven by increasing disease awareness, rising exposure to indoor allergens, improving diagnosis rates, and the growing adoption of immunotherapy. Additionally, the launch of emerging therapies such as LY3650150 (lebrikizumab, … Continue reading →

X-Linked Retinitis Pigmentosa (XLRP) Market is Projected to Boom by 2036 Owing to the Launch of Novel Gene Therapies | DelveInsight

The market dynamics for X-Linked Retinitis Pigmentosa (XLRP) is witnessing steady growth driven by increasing awareness of inherited retinal disorders, advances in genetic diagnosis, expanding research in retinal gene therapy, and growing investment in precision medicine. Additionally, the launch of … Continue reading →

Lyme Disease Market is Projected to Boom by 2036 Owing to the Launch of Novel Therapies | DelveInsight

The market dynamics for Lyme Disease is witnessing steady growth driven by the increasing incidence of tick-borne infections, expanding geographic distribution of disease-carrying ticks, growing awareness of early diagnosis and treatment, and the development of innovative prophylactic and therapeutic approaches. … Continue reading →

Gastric Cancer Pipeline Appears Robust With 200+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s “Gastric Cancer Pipeline Insight 2026” report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in the Gastric Cancer pipeline landscape. It covers the Gastric Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Non Small Cell Lung Cancer Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s “NSCLC Pipeline Insight 2026” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in the NSCLC pipeline landscape. It covers the NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NSCLC pipeline … Continue reading →

Osteoporosis Pipeline Expands as 30+ Companies Advance Innovative Bone Health Therapies, Finds DelveInsight

There are 30+ key companies, including Alvotech, Transcenta Holding, GlycoNex, and others, developing therapies for Osteoporosis across multiple stages of clinical development. The competitive landscape is characterized by a focus on novel monoclonal antibodies, biosimilars, and small molecules aimed at … Continue reading →

Small Lymphocytic Lymphoma Pipeline Gains Momentum: 80+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Small Lymphocytic Lymphoma Pipeline Insight, 2026” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Small Lymphocytic Lymphoma pipeline landscape. It covers the Small Lymphocytic Lymphoma pipeline drug profiles, including clinical and non-clinical stage products. It … Continue reading →

Knee Osteoarthritis Pipeline Gains Momentum: 55+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Knee Osteoarthritis Pipeline Insight 2026” report provides comprehensive insights about 55+ companies and 65+ pipeline drugs in the Knee Osteoarthritis pipeline landscape. It covers the Knee Osteoarthritis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →